The purpose of this study is to assess COVID-19 prophylactic/therapeutic safety and effectiveness in transplant patients, assess mental health impacts of COVID-19 on transplant patients and families, develop strategies to improve well-being, and determine the economic burden and value of emerging and existing prophylactic/therapeutic options for COVID-19 in transplant patients.
The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for patients with type 1 diabetes who have a kidney transplant.
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with chronic graft-versus-host disease.
The purpose of this study is to understand and document the experiences of patients who live at least 60 minutes outside of the Lower Mainland and who are traveling to Vancouver for a solid organ transplant. The research team aims to document the psychological, social, emotional and cultural impact for patients leaving their communities to access care in Vancouver. The study will also capture the associated out-of-pocket costs that these transplant patients incur before, during and after the transplant operation.
The purpose of this study is to help the study sponsor determine whether adding the study drug, belumosudil, to usual treatment (immunosuppression per transplant site and azithromycin) is better, the same or worse than the usual treatment approach alone for chronic lung rejection.
The purpose of this study is to determine whether an oral vitamin called nicotinamide can help prevent skin cancer in 396 high-risk kidney, liver, heart and lung transplant recipients. Participants will be involved in the study for four years and will visit the study doctor or clinical research staff every 17 weeks. Participants will receive nicotinamide or a placebo, taken orally for the entire follow-up period, which will last up to 208 weeks.
The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for type 1 diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar.
The purpose of this study is to assess the overall efficacy, safety and tolerability of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients.
The purpose of this study is to evaluate the immune response and safety of a new vaccine in preventing diseases due to infection with respiratory syncytial virus (RSV). This RSV vaccine will be tested in older adults who are recipients of lung or kidney transplants and are at an increased risk of RSV compared to healthy older adults.
The purpose of the study is to investigate the safety and efficacy of itolizumab versus placebo in individuals with acute graft-versus-host disease, when combined with corticosteroids as a first line treatment.
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
The purpose of this study is to determine if coronary artery disease (CAD) screening is necessary for patients on the waiting list for kidney transplantation. Patients on the waiting list for kidney transplantation are at risk for CAD. Currently, patients without any symptoms of CAD undergo annual testing to determine if they have disease. The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown.
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation have not been achieved. The specific drug combination that provides the best outcomes with the least amount of side effects is not known. Each kidney transplant center uses the combination of drugs that they believe is optimal.
The purpose of this study is to evaluate the efficacy, safety and tolerability of axatilimab at three different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least two prior lines of systemic therapy.